Vaxart (VXRT) Proxy filing summary

Executive summary

• Annual Meeting scheduled for July 16, 2026, with a focus on voting for six incumbent director nominees.

• Emphasis on the importance of experienced biotech leadership to advance clinical and strategic priorities.

• Multiple operational and clinical milestones are approaching, including BARDA-funded COVID-19 trials and norovirus vaccine advancement.

• Forward-looking statements highlight expectations for clinical results, partnerships, and capital resources.

Voting matters and shareholder proposals

• Shareholders are urged to vote “FOR” all six incumbent director nominees on the WHITE proxy card.

• A small group of shareholders is proposing alternative nominees lacking relevant biotech and public company experience.

• Board warns that replacing current directors could disrupt execution and risk shareholder value.

Board of directors and corporate governance

• Board intentionally composed of directors with expertise in biotech development, commercialization, and regulatory affairs.

• Two new directors appointed in the last 18 months, reducing average tenure to 2.3 years.

• CEO Steve Lo joined in March 2024, credited with securing key funding and partnerships.

• Board continues to engage with shareholders and adapt based on feedback.